Francisco Marín Ortuño-rekin lankidetzan egindako argitalpenak (5)

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

2018

  1. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU

    Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 553-564

2016

  1. On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013

    Revista Espanola de Cardiologia, Vol. 69, Núm. 6, pp. 551-553

2012

  1. Comments on the ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation. A report of the task force of the clinical practice guidelines committee of the Spanish society of cardiology

    Revista Espanola de Cardiologia, Vol. 65, Núm. 2, pp. 125-130

2010

  1. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation

    Circulation, Vol. 122, Núm. 10, pp. 1017-1025